• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

Recent Advances in the Application of tert-Butyl 3-(aminomethyl)-4-fluoropiperidine-1-carboxylate (CAS: 1303973-02-5) in Chemical Biology and Pharmaceutical Research

The compound tert-Butyl 3-(aminomethyl)-4-fluoropiperidine-1-carboxylate (CAS: 1303973-02-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This fluorinated piperidine derivative serves as a versatile building block in medicinal chemistry, particularly in the synthesis of bioactive molecules targeting central nervous system (CNS) disorders and other therapeutic areas. Its unique structural features, including the fluorinated aromatic ring and the protected amine group, make it an attractive intermediate for drug discovery programs.

Recent studies have demonstrated the utility of 1303973-02-5 in the synthesis of novel kinase inhibitors and G protein-coupled receptor (GPCR) modulators. A 2023 publication in the Journal of Medicinal Chemistry highlighted its application in developing selective dopamine D3 receptor antagonists, showing improved blood-brain barrier penetration compared to non-fluorinated analogs. The fluorination at the 4-position of the piperidine ring was found to significantly enhance metabolic stability while maintaining target affinity.

In synthetic methodology, researchers have developed improved protocols for the Boc-deprotection and subsequent functionalization of 1303973-02-5. A recent patent application (WO2023056123) describes a highly efficient two-step conversion to various secondary amines under mild conditions, preserving the stereochemical integrity of the molecule. This advancement has important implications for the scalable production of derivatives for structure-activity relationship studies.

Pharmacokinetic studies of derivatives containing this scaffold have shown promising results. A 2024 preclinical study demonstrated that compounds derived from 1303973-02-5 exhibit favorable absorption and distribution profiles, with particular advantages in CNS-targeted therapies. The fluorinated piperidine core appears to reduce P-glycoprotein-mediated efflux, addressing a common challenge in neuropharmaceutical development.

Emerging applications extend beyond traditional small molecule drugs. Recent work published in Bioconjugate Chemistry (2024) reports the use of 1303973-02-5 as a linker in antibody-drug conjugates (ADCs). The stability of the fluorinated piperidine moiety under physiological conditions, combined with its predictable cleavage characteristics, makes it particularly suitable for this application.

Ongoing research is exploring the potential of this scaffold in targeted protein degradation strategies. Preliminary results suggest that derivatives of 1303973-02-5 can serve as effective E3 ligase-recruiting elements in proteolysis-targeting chimeras (PROTACs), with the fluorination pattern contributing to optimal ternary complex formation.

As the pharmaceutical industry continues to seek novel chemical space for drug discovery, 1303973-02-5 and its derivatives represent an important area of investigation. The compound's unique combination of synthetic accessibility, structural diversity potential, and favorable physicochemical properties positions it as a valuable tool in modern medicinal chemistry efforts.

• 1334416-43-1(tert-butyl 4-(aMinoMethyl)-3-fluoro-4-Methylpiperidine-1-carboxylate)
• 1303972-96-4(tert-butyl 4-(aminomethyl)-3-fluoropiperidine-1-carboxylate)
• 1263177-23-6(tert-butyl 10-fluoro-2,7-diazaspiro[4.5]decane-7-carboxylate)
• 1250998-80-1(tert-Butyl 5-fluoro-2,7-diazaspiro[3.5]nonane-7-carboxylate)
• 1237526-35-0(tert-butyl cis-4-(aminomethyl)-3-fluoro-piperidine-1-carboxylate)
• 620611-27-0(Tert-butyl 4-(aminomethyl)-4-fluoropiperidine-1-carboxylate)
• 1303973-27-4(Tert-butyl 3-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate)
• 1263178-67-1(tert-butyl 5-fluoro-2,7-diazaspiro[3.5]nonane-2-carboxylate)
• 1404196-62-8(di-tert-butyl4,4'-azanediylbis(methylene)bis(3-fluoro-4-methylpiperidine-1-carboxylate)-D28120)
• 1263177-97-4(tert-butyl 9,9-difluoro-2,6-diazaspiro[3.5]nonane-6-carboxylate)